

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-780

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-780

NovaDel Pharma Inc.
Attention: Gary Shangold, M.D.
25 Minneakoning Rd.
Flemington, NJ 08822

Dear Dr. Shangold:

Please refer to your new drug application (NDA) dated June 17, 2004, received August 4, 2004 (date removed from Arrears List) and resubmitted April 28, 2006 under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for NitroMist™ (Nitroglycerin) Lingual Aerosol 400 mcg/actuation.

We acknowledge receipt of your submissions dated April 28 (three), June 29 (two), June 30, July 7, August 2, 16 and October 30, 2006.

Your April 28, 2006 submission constituted a complete response to our May 31, 2005 action letter.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

This new drug application provides for the use of NitroMist™ (Nitroglycerin) Lingual Aerosol 400 mcg/actuation for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and immediate container) and carton labels included in your submission dated October 30, 2006. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical in content to the enclosed labeling text. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We reference our letter dated July 14, 2004 granting a full waiver for pediatric studies for this application.

Please note the following stability comments:

1. The formal stability study of the GTN Basic Solution failed to monitor the degradants; accordingly, the GTN Basic Solution should be tested prior to each use, until an extended holding period is established based on appropriate stability data, which includes monitoring of the degradation products.

2. The formal stability study of the drug product indicated a steady decline (decrease to the lower limit of acceptability) in the level of drug substance (measured as assay of nitroglycerin) with time and temperature and hence, an 18-month shelf-life is acceptable.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Cardiovascular and Renal Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you have any questions, please call Mr. John David, Regulatory Project Manager, at (301) 796-1059

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: agreed-upon labeling text

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
11/2/2006 12:55:51 PM